Grauer L S, Finlay J A, Mikolajczyk S D, Pusateri K D, Wolfert R L
Hybritech Incorporated, a subsidiary of Beckman Instruments, Incorporated, San Diego, California 92196-9006, USA.
J Androl. 1998 Jul-Aug;19(4):407-11.
Forms of human glandular kallikrein (kK2) in prostate carcinoma serum were identified using monoclonal antibodies specific for hK2 and prohK2. Recombinant mammalian hK2, prohK2, and prostate = specific antigen (PSA) were utilized to confirm the specificity of monoclonal antibodies for hK2 and the lack of reactivity with PSA. In prostate cancer patient sera containing high levels of hK2 (>100 ng/ml), hK2 exists as a complex with alpha1-antichymotrypsin with a molecular weight of 90 kDa. The kallikrein also exists as a 32-kDa free form, which includes the precursor pro form of hK2. The relative amount of complex and free hK2 varied, but in most sera examined the 32-kDa form predominated. Recombinant hK2 readily formed complexes with alpha2-macroglobulin when the two proteins were incubated together as well as when hK2 was spiked into female serum.
利用对人组织激肽释放酶2（hK2）和前体hK2（prohK2）具有特异性的单克隆抗体，鉴定前列腺癌血清中人类腺组织激肽释放酶（kK2）的形式。使用重组哺乳动物hK2、prohK2和前列腺特异性抗原（PSA）来确认单克隆抗体对hK2的特异性以及与PSA无反应性。在含有高水平hK2（>100 ng/ml）的前列腺癌患者血清中，hK2以与α1-抗糜蛋白酶形成的分子量为90 kDa的复合物形式存在。激肽释放酶也以32 kDa的游离形式存在，其中包括hK2的前体形式。复合物形式和游离hK2的相对量有所不同，但在大多数检测的血清中，32 kDa形式占主导。当重组hK2与α2-巨球蛋白一起孵育时，以及当hK2加入女性血清中时，重组hK2很容易与α2-巨球蛋白形成复合物。
